José Baselga, MD, PhD
The combination of durvalumab (Imfinzi) and tremelimumab did not improve overall survival (OS) compared with standard platinum-based chemotherapy in previously untreated patients with stage IV metastatic non–small cell lung cancer (NSCLC) who have tumor mutational burden (TMB) ≥20 mutations/megabase (mut/mB), missing the primary endpoint of the phase III NEPTUNE trial (NCT02542293).1
- Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in stage IV non-small cell lung cancer. AstraZeneca. Published August 21, 2019. https://bit.ly/2TPGs2Y. Accessed August 21, 2019.
- Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. Ann Oncol. 2018;29(10). doi: 10.1093/annonc/mdy511.005.
... to read the full story